Abstract Number: 1465 • 2012 ACR/ARHP Annual Meeting
World Health Organization Classification of Pulmonary Hypertension and Survival in Systemic Sclerosis Patients in the Pharos Cohort
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH…Abstract Number: 1466 • 2012 ACR/ARHP Annual Meeting
Patients with Systemic Sclerosis Are Dying of Non-Systemic Sclerosis Related Causes, However Interstitial Lung Disease Remains the Predominant Systemic Sclerosis Related Cause of Death
Interstitial Lung Disease Remains the leading Cause of Death in Patients with Systemic Sclerosis, Despite Aggressive Treatment with CyclophosphamideBackground/Purpose: Studies suggest that despite aggressive treatment…Abstract Number: 1467 • 2012 ACR/ARHP Annual Meeting
Association of Gastroesophageal Factors and Progression of Interstitial Lung Disease in the Canadian Scleroderma Research Group, a Large, Multicenter Database
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is a leading contributor to mortality in SSc patients. Once lung…Abstract Number: 1468 • 2012 ACR/ARHP Annual Meeting
Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease
Background/Purpose: Limited information on the patient experience exists in CTD-ILD. Herein supports that the patients' perspective is essential to informing clinical practice and in…Abstract Number: 1470 • 2012 ACR/ARHP Annual Meeting
Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?
Background/Purpose: Autoantibodies in scleroderma (systemic sclerosis, SSc) such as anti-topoisomerase I (Scl-70), RNA polymerase III, centromere, U3RNP/fibrillarin, and Th/To are associated with a unique subset…Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…Abstract Number: 1472 • 2012 ACR/ARHP Annual Meeting
Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis
Background/Purpose: Enhanced Liver Fibrosis (ELF) test is derived from an algorithm of 3 serum biomarkers of fibrosis (i.e. tissue inhibitors of matrix metalloproteinases, hyaluronic acid…Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…Abstract Number: 1474 • 2012 ACR/ARHP Annual Meeting
Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis
Plasma Interferon Inducible Chemokine Score: Stable Marker of Disease Severity in Systemic SclerosisABSTRACT:Background/Purpose: The most prominent gene expression profile in the peripheral blood of patients…Abstract Number: 1475 • 2012 ACR/ARHP Annual Meeting
Does Skin Gene Expression Profile Predict Response to Imatinib?
Background/Purpose: Imatinib is a potent inhibitor of TGF-β signaling. Furthermore, a subgroup of SSc patients shows a prominent TGF-β gene expression signature in skin biopsy…Abstract Number: 1476 • 2012 ACR/ARHP Annual Meeting
Caveolin-1 Deficiency May Play a Role in the Predisposition of African Americans to SSc ILD
Background/Purpose: Scleroderma-associated Interstitial Lung Disease (SSc-ILD) is more prevalent and more severe in African Americans (AA) than in Caucasian (C) patients, but little is known…Abstract Number: 1436 • 2012 ACR/ARHP Annual Meeting
Application of European League Against Rheumatism Recommendations for the Management of Systemic Lupus Erythematosus Patients with Neuropsychiatric Involvement May Limit Unnecessary Diagnostic Testing and Curve Intensification of Immunosuppressive Therapy of Unclear Benefit
Background/Purpose: Systemic lupus erythematosus (SLE) patients may experience a wide variety of neurological and psychiatric manifestations (neuropsychiatric [NP] SLE [NPSLE]), which pose diagnostic and therapeutic…Abstract Number: 1437 • 2012 ACR/ARHP Annual Meeting
Majority of Lupusqol Domains Are Negatively Correlated with Systemic Lupus Activity Questionnaire (SLAQ) Score
Background/Purpose: Systemic lupus erythematosus (SLE) disease activity measures such as the SLEDAI and BILAG require real time physician and laboratory assessment of patients, making them…Abstract Number: 1438 • 2012 ACR/ARHP Annual Meeting
Development of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice in the Absence of Any Single BAFF Receptor
Background/Purpose: To determine the necessity for any individual BAFF receptor in the development of SLE. Methods: NZM 2328 wild-type (WT), NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/-mice were…Abstract Number: 1439 • 2012 ACR/ARHP Annual Meeting
CTL-Promoting Effects of IL-21 Results in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
Background/Purpose: IL-21 is a member of the type I cytokine family with pleiotropic activities. IL-21 enhances CD8 T cells maturation into cytotoxic T lymphocytes (CTL),…